Lung Cancer: Xavier's Patient Story

Patient Info: Xavier Sanders, Male | Stage Metastatic/Advanced

Metastatic Site: kidneys

Xavier’s lung disease had cleared, but cancer in his kidneys remained under treatment with 2 pills daily and checkups every 3 months; he reported major improvement in his mental health after seeking help.

Stage IV Lung Cancer: Angie's Patient Story

Patient Info: Angie Brice Hessbruegge, Female, Under 40 | Stage IV

Angie remained on chemotherapy and focused on parenting, counseling, faith, and long-term survivor stories while living with Stage IV lung cancer.

Stage IV ALK Lung Cancer: Michelle's Patient Story

Patient Info: Michelle, Female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: leptomeninges and cerebrospinal fluid / central…

Targeted therapy and proton craniospinal irradiation eliminated detectable leptomeningeal disease. Treatment side effects later passed, and Michelle continued rehabilitation.

Stage IV Lung Cancer: Hakim's Patient Story

Patient Info: Hakim Rusli, Male | Stage IV

Metastatic Site: Brain

Stage IV lung cancer with brain metastasis became controlled after care at Modern Cancer Hospital Guangzhou; progression slowed and symptoms/supportive issues were managed, but no remission or NED status is reported.

Stage IV Lung Cancer: Mila's Patient Story

Patient Info: Mila Gardon, Female, 50s | Stage IV

Metastatic Site: Neck lymph nodes; skull; iliac bone

Stage IV lung cancer with spread to neck lymph nodes, skull, and iliac bone responded after cryotherapy and interventional therapy; lung tumors disappeared and tumor marker normalized, but the source does not state full remission or NED.

Stage IV ALK Lung Cancer: Jay's Survivor Story

Patient Info: Jay Petri, Male | Stage IV

Biomarkers: ALK mutation / ALK-rearranged lung cancer

Metastatic Site: Not reported

Stage IV ALK-positive lung cancer treated through clinical trials at Mass General; he reported being cancer-free for nearly 1.5 years after going through 3 trials.

Massachusetts General HospitalRead more →

Stage III ALK Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Bos-Lun, Female | Stage III

Biomarkers: ALK-positive

Stage IIIB ALK-positive lung cancer responding to Lorbrena/lorlatinib, with cough improvement within days and first scan showing nearly 50% tumor reduction.

GO2 FoundationRead more →

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed CentralRead more →

Lung cancer first discovered after a small-bowel blockage

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: jejunum|brain|bone

The cancer progressed to the brain and spine despite chemotherapy, and he was admitted to palliative care.

PubMed CentralRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

RET-positive Stage IV lung cancer: targeted therapy stopped after severe side effects

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: RET fusion

Metastatic Site: brain|bone

Selpercatinib produced early shrinkage of the lung tumor and brain metastases, but it was permanently discontinued because of recurrent severe side effects. She was transferred for supportive care.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed CentralRead more →

Stage IVA lung squamous cell carcinoma with immune-checkpoint-inhibitor-associated Graves thyroid storm

Patient Info: Anonymized, Male | Stage IV

Biomarkers: Cancer biomarkers not reported. Thyroid storm workup had TSAb/TRAb positivity consistent with Graves disease.

Metastatic Site: not specified in extracted case text

After thyroid storm improved with antithyroid therapy and supportive care, the patient was transferred for further lung-cancer treatment but died of progressive lung cancer about 2 months later.

PubMed CentralRead more →

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed CentralRead more →

Lung cancer treated with tislelizumab: rare fluid buildup around the lung as a side effect

Patient Info: Anonymized, Male, 60s

After treatment of the bronchial-stump recurrence, the tumor remained stable. The delayed pleural effusion resolved within 10 days of methylprednisolone, and tumor stability continued for the next 15 months.

PubMed CentralRead more →

Stage IIIA small-cell lung cancer with anti-NMDAR encephalitis: initial complete response, recurrence, and death

Patient Info: Anonymized, Male, 60s

Biomarkers: CSF positive for anti-NMDAR antibodies; no tumor molecular biomarkers reported

The patient initially had rapid neurologic recovery and complete radiologic response after carboplatin, etoposide, and atezolizumab, but the primary lung lesion recurred 7 months later and he died 21 months after disease onset.

PubMed CentralRead more →

Stage IVA EGFR-mutated lung adenocarcinoma: stable disease on first-line osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; baseline EGFR exon 20 T790M mutation; ALK IHC negative; PD-L1 TPS 30%; TTF-1-positive

Metastatic Site: pleura; malignant pleural-pericardial adhesions

As of April 2026, she had stable disease for more than 9 months on first-line osimertinib, with no progressive disease, no recurrent pleural effusion, ECOG improvement from 2 to 0, and no treatment-related adverse events.

PubMed CentralRead more →

Stage IV squamous NSCLC: durable pembrolizumab response followed by invasive aspergillosis, marrow failure, and death

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 20%

Metastatic Site: bilateral lungs

After durable partial response to pembrolizumab-based therapy, he developed severe pulmonary infection, invasive pulmonary aspergillosis, progressive AA-like bone marrow failure with severe cytopenias, declined further treatment, and died at home in early 2025.

PubMed CentralRead more →

Pulmonary nodules mimicking lung cancer in MPO-ANCA vasculitis with kidney injury

Patient Info: Anonymized, Female, Under 40

Biomarkers: Initial vasculitis/kidney markers: MPO-ANCA and anti-GBM positive, high creatinine/proteinuria, anemia.

As of November 20, 2023, kidney function had improved, dialysis was stopped, ANCA/GBM antibodies were negative, pulmonary nodules were much smaller, and she was maintained on azathioprine 100 mg daily.

PubMed CentralRead more →

Early-stage synchronous lung cancers: tumor-free after lobectomy with delayed respiratory and neuropsychiatric complications

Patient Info: Anonymized, Male, 60s

Biomarkers: No molecular biomarkers reported

More than 3 years after thoracoscopic right middle and lower lobectomy, he remained tumor-free, although he had delayed cardiopulmonary, weight-loss, and neuropsychiatric complications after surgery.

PubMed CentralRead more →

Stage IV squamous lung cancer with steroid-refractory immune-related gastritis after pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Gastric biopsy during immune gastritis showed CD8-positive lymphocyte inflammation, no cancer

After about 2 years of carboplatin, pemetrexed, and pembrolizumab, lung cancer treatment was stopped because of tumor growth; the later immune-related gastritis improved after escalation to infliximab, while the cancer course remained a setback/progression story.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: major pathological response after neoadjuvant immunochemotherapy, complicated by DILI/TEN

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: No lung molecular biomarkers reported

At 23 months after thoracoscopic left upper lobectomy, he was clinically stable with no evidence of tumor recurrence; severe postoperative DILI/TEN had improved after stopping the offending drug and intensive supportive treatment.

PubMed CentralRead more →

Small-cell lung cancer: envafolimab response complicated by immune-related diabetes, pneumonitis, and later submandibular progression

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: ProGRP and NSE were elevated at diagnosis. Tumor molecular biomarkers were not reported; diabetes antibodies were negative.

Metastatic Site: left submandibular region / adjacent lymph nodes

After initial partial response on envafolimab, carboplatin, etoposide, and thoracic radiotherapy, he developed immune-related diabetes, pneumonitis, and progressive left submandibular metastatic disease requiring iodine-125 seeds and later anlotinib.

PubMed CentralRead more →